BCR and mantle cell lymphoma: Recurrent mutations in MCL patients who have relapsed on ibrutinib have also been found in CARD11, a protein responsible for BCR-induced NFκB activation, or in CCND1, a cyclin that promotes G1-S cell cycle progression (24, 81, 86).